Poradosu Enrique
SEC CIK 1898147 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVCT | Nuvectis Pharma, Inc. | Chief Science, Business Off | 1.81M | $45.0K | — | 10 | 2022-02-04 | 2026-01-06 |
Most active insiders at NVCT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Mosseri Marlio Charles | 10% | $1.87M | — |
| 2 | BENTSUR RON | COB, CEO, Dir, 10% | $278.6K | — |
| 3 | Sanchez Juan | Dir | $75.3K | — |
| 4 | Kaplan Matthew L. | Dir | $64.2K | — |
| 5 | Poradosu Enrique | Chief Science, Business Off | — | — |
| 6 | Carson Michael J. | VP, Fin | — | — |
| 7 | Shemesh Shay | Chief Dev, Ops. Off | — | — |
| 8 | Hoberman Kenneth | Dir | — | — |
| 9 | Oliviero James F III | Dir | — | — |
Transactions 10
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-09 | 2026-01-06 | NVCT | Nuvectis Pharma, Inc. | Poradosu Enrique | Chief Science, Business Off | A - Grant | $0.00 | +150.0K | 1.81M | +9% | $0 | |
| 2025-01-03 | 2025-01-02 | NVCT | Nuvectis Pharma, Inc. | Poradosu Enrique | Chief Science, Business Off | A - Grant | $0.00 | +150.0K | 1.66M | +10% | $0 | |
| 2024-11-20 | 2024-11-19 | NVCT | Nuvectis Pharma, Inc. | Poradosu Enrique | Chief Science, Business Off | P - Purchase | $4.99 | +2,000 | 1.51M | +0.1% | +$9,980 | |
| 2024-05-13 | 2024-05-10 | NVCT | Nuvectis Pharma, Inc. | Poradosu Enrique | Chief Science, Business Off | P - Purchase | $6.29 | +500 | 1.50M | +0.0% | +$3,145 | |
| 2024-01-05 | 2024-01-03 | NVCT | Nuvectis Pharma, Inc. | Poradosu Enrique | Chief Science, Business Off | A - Grant | $0.00 | +130.0K | 1.50M | +9% | $0 | |
| 2023-03-28 | 2023-03-27 | NVCT | Nuvectis Pharma, Inc. | Poradosu Enrique | Chief Science, Business Off | P - Purchase | $11.55 | +500 | 1.37M | +0.0% | +$5,775 | |
| 2023-01-13 | 2023-01-12 | NVCT | Nuvectis Pharma, Inc. | Poradosu Enrique | Chief Science, Business Off | A - Grant | $0.00 | +115.0K | 1.37M | +9% | $0 | |
| M | 2022-05-16 | 2022-05-12 | NVCT | Nuvectis Pharma, Inc. | Poradosu Enrique | Chief Science, Business Off | P - Purchase | $15.33 | +670 | 1.26M | +0.1% | +$10.3K |
| 2022-04-05 | 2022-04-01 | NVCT | Nuvectis Pharma, Inc. | Poradosu Enrique | Chief Science, Business Off | A - Grant | $0.00 | +60.0K | 1.26M | +5% | $0 | |
| M | 2022-02-08 | 2022-02-04+ | NVCT | Nuvectis Pharma, Inc. | Poradosu Enrique | Chief Science, Business Off | P - Purchase | $3.44 | +4,600 | 1.20M | +0.4% | +$15.8K |
Purchase Sale Sale after option exercise All abbreviations